Research Reports Initiation on Healthcare Stocks -- Palatin Technologies, AMAG Pharma, IDEXX Labs, and Delcath Systems

Monday, February 6, 2017 Research News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, February 6, 2017 /PRNewswire/ --

On Friday, February 03, 2017, US markets

saw broad based gains with all sectors finishing the trading sessions in green. Major US indices were also bullish at the close of last Friday's session. The NASDAQ Composite ended the day at 5,666.77, up 0.54%; the Dow Jones Industrial Average edged
0.94% higher, to finish at 20,071.46; and the S&P 500 closed at 2,297.42, up 0.73%. This Monday morning, looks at the performance of these four Healthcare stocks: Palatin Technologies Inc. (NYSE MKT: PTN), AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), IDEXX Laboratories Inc. (NASDAQ: IDXX), and Delcath Systems Inc. (NASDAQ: DCTH). You can access our complimentary research reports on these stocks now at:

Palatin Technologies  

Cranbury, New Jersey-based Palatin Technologies Inc.'s stock advanced 5.86%, to close the day at $0.44. The stock recorded a trading volume of 8.50 million shares, which was above its three months average volume of 2.62 million shares. The Company's shares are trading 15.23% and 17.36% below its 50-day and 200-day moving averages, respectively. Additionally, shares of the Company, which develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the US, have a Relative Strength Index (RSI) of 45.17. Visit us today and download your complete report on PTN for free at:

AMAG Pharma  

On Friday, shares in Waltham, Massachusetts headquartered AMAG Pharmaceuticals Inc. ended the session 1.84% higher at $22.10 with a total volume of 1.21 million shares traded. Shares of the Company, which provides products and services with a focus on maternal health, anemia management, and cancer supportive care in the US, are trading at a PE ratio of 63.32. The stock is trading 27.26% below its 50-day moving average and 14.78% below its 200-day moving average. Moreover, the Company's shares have an RSI of 32.09.

On January 11th, 2017, research firm Needham downgraded the Company's stock rating from 'Buy' to 'Hold'. The complimentary research report on AMAG can be accessed at:

IDEXX Laboratories  

On Friday, shares in Westbrook, Maine headquartered IDEXX Laboratories Inc. recorded a trading volume of 1.76 million shares, which was higher than their three months average volume of 955,240 shares. The stock ended the day 2.12% lower at $142.02. The Company's shares are trading at a PE ratio of 60.38. IDEXX Labs' stock has surged 22.48% in the last one month and 34.69% in the previous three months. Furthermore, the stock has rallied 100.25% in the past one year. The Company is trading below its 50-day and 200-day moving averages by 18.93% and 34.99%, respectively. Furthermore, shares of IDEXX Labs, which together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, water testing, and dairy markets worldwide, have an RSI of 83.05.

On February 03rd, 2017, research firm Feltl & Co. downgraded the Company's stock rating from 'Hold' to 'Sell'. Register for free on and download the PDF research report on IDXX at:

Delcath Systems  

New York headquartered Delcath Systems Inc.'s stock finished Friday's session 4.74% higher at $0.32 with a total volume of 4.98 million shares traded. The Company's shares are trading below its 50-day and 200-day moving averages by 71.23% and 98.73%, respectively. Shares of Delcath Systems, which operates as a specialty pharmaceutical and medical device company focusing on cancers of the liver, have an RSI of 26.25. Get free access to your research report on DCTH at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store